{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:26:24Z","timestamp":1793042784996,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s43440-026-00859-1","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:31:29Z","timestamp":1778232689000},"page":"762-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The novel third-generation antipsychotic drug brexpiprazole affects hepatic transcription factors, serum hormone levels, and cytochrome P450 enzymes after prolonged treatment: pharmacological significance"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-2990","authenticated-orcid":false,"given":"Przemys\u0142aw J.","family":"Danek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4820-9084","authenticated-orcid":false,"given":"Renata","family":"Puk\u0142o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1226-1721","authenticated-orcid":false,"given":"W\u0142adys\u0142awa A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"5","key":"859_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","volume":"16","author":"RB Mailman","year":"2010","unstructured":"Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? CPD. 2010;16(5):488. https:\/\/doi.org\/10.2174\/138161210790361461.","journal-title":"CPD"},{"issue":"9","key":"859_CR2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","volume":"172","author":"CU Correll","year":"2015","unstructured":"Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and Safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week Randomized, Double-blind, placebo-controlled Trial. AJP. 2015;172(9):870\u201380. https:\/\/doi.org\/10.1176\/appi.ajp.2015.14101275.","journal-title":"AJP"},{"issue":"18","key":"859_CR3","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.3390\/ijms231810624","volume":"23","author":"J Orzelska-G\u00f3rka","year":"2022","unstructured":"Orzelska-G\u00f3rka J, Mikulska J, Wiszniewska A, Bia\u0142a G. New atypical antipsychotics in the treatment of schizophrenia and depression. IJMS. 2022;23(18):10624. https:\/\/doi.org\/10.3390\/ijms231810624.","journal-title":"IJMS"},{"issue":"4","key":"859_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/YIC.0000000000000559","volume":"40","author":"V Ricci","year":"2025","unstructured":"Ricci V, Sarni A, Martinotti G, Maina G. Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review. Int Clin Psychopharmacol. 2025;40(4):191\u2013206. https:\/\/doi.org\/10.1097\/YIC.0000000000000559.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"859_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40263-016-0325-8","volume":"30","author":"KP Garnock-Jones","year":"2016","unstructured":"Garnock-Jones KP. Brexpiprazole: a review in schizophrenia. CNS Drugs. 2016;30(4):335\u201342. https:\/\/doi.org\/10.1007\/s40263-016-0325-8.","journal-title":"CNS Drugs"},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.2147\/DDDT.S240859","volume":"14","author":"Y Watanabe","year":"2020","unstructured":"Watanabe Y, Yamada S, Otsubo T, Kikuchi T. Brexpiprazole for the treatment of schizophrenia in adults: an overview of its clinical efficacy and Safety and a Psychiatrist\u2019s perspective. DDDT 2020, 14: 5559\u201374. https:\/\/doi.org\/10.2147\/DDDT.S240859.","journal-title":"DDDT"},{"issue":"7","key":"859_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/07067437241233965","volume":"69","author":"F Therrien","year":"2024","unstructured":"Therrien F, Ward C, Chokka P, Habert J, Ismail Z, McIntyre RS, et al. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d\u2019appoint pour l\u2019engagement dans la vie des patients souffrant de trouble d\u00e9pressif majeur: une \u00e9tude interventionnelle canadienne ouverte de phase 4. Can J Psychiatry. 2024;69(7):513\u201323. https:\/\/doi.org\/10.1177\/07067437241233965.","journal-title":"Can J Psychiatry"},{"key":"859_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/NDT.S501207","volume":"21","author":"M Brubaker","year":"2025","unstructured":"Brubaker M, Kapadia S, Maletic V, Chambers JS, Watling CP, Citrome L. Preclinical evidence for the use of brexpiprazole + antidepressant treatment for Major Depressive Disorder and Post-traumatic Stress Disorder: a systematic review. NDT. 2025;21:421\u201336. https:\/\/doi.org\/10.2147\/NDT.S501207.","journal-title":"NDT"},{"key":"859_CR9","doi-asserted-by":"publisher","unstructured":"Giacovelli L, Piccoli E, Landi P, Vismara M, Benatti B, Dell\u2019osso B. Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study. Int Clin Psychopharmacol. 2025;40(6):e14\u201320. https:\/\/doi.org\/10.1097\/YIC.0000000000000583.","DOI":"10.1097\/YIC.0000000000000583"},{"issue":"3","key":"859_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1001\/jamapsychiatry.2024.3996","volume":"82","author":"LL Davis","year":"2025","unstructured":"Davis LL, Behl S, Lee D, Zeng H, Skubiak T, Weaver S, et al. Brexpiprazole and sertraline combination treatment in posttraumatic Stress Disorder: a Phase 3 Randomized clinical Trial. JAMA Psychiatry. 2025;82(3):218\u201327. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3996.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"859_CR11","doi-asserted-by":"publisher","first-page":"105173","DOI":"10.1016\/j.jamda.2024.105173","volume":"25","author":"D Lee","year":"2024","unstructured":"Lee D, Clark ED, Antonsdottir IM, Porsteinsson AP. Brexpiprazole for Agitation Associated with Dementia due to Alzheimer\u2019s Disease. J Am Med Dir Assoc. 2024;25(10):105173. https:\/\/doi.org\/10.1016\/j.jamda.2024.105173.","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"859_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-024-01133-9","volume":"39","author":"C Imbimbo","year":"2025","unstructured":"Imbimbo C, Cotta Ramusino M, Leone S, Mazzacane F, De Franco V, Gatti A, et al. Emerging pharmacological approaches for psychosis and Agitation in Alzheimer\u2019s Disease. CNS Drugs. 2025;39(2):143\u201360. https:\/\/doi.org\/10.1007\/s40263-024-01133-9.","journal-title":"CNS Drugs"},{"issue":"3","key":"859_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.114.213819","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605\u201314. https:\/\/doi.org\/10.1124\/jpet.114.213819.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"859_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"859_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/00498254.2021.1890275","volume":"51","author":"H Sasabe","year":"2021","unstructured":"Sasabe H, Koga T, Furukawa M, Matsunaga M, Kaneko Y, Koyama N, et al. Pharmacokinetics and metabolism of brexpiprazole, a novel serotonin-dopamine activity modulator and its main metabolite in rat, monkey and human. Xenobiotica 2021. 2021;51(5):590\u2013604. https:\/\/doi.org\/10.1080\/00498254.2021.1890275.","journal-title":"Xenobiotica 2021"},{"issue":"5","key":"859_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1080\/00498254.2021.1897898","volume":"51","author":"H Sasabe","year":"2021","unstructured":"Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Hashizume K, et al. In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. Xenobiotica 2021. 2021;51(5):522\u201335. https:\/\/doi.org\/10.1080\/00498254.2021.1897898.","journal-title":"Xenobiotica 2021"},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"101057","DOI":"10.1016\/j.dmpk.2025.101057","volume":"62","author":"K Higashi","year":"2025","unstructured":"Higashi K, Sasaki T, Aoki K, Sekine D, Maeda K, Shiomi Y, et al. Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia. Drug Metab Pharmacokinet. 2025;62:101057. https:\/\/doi.org\/10.1016\/j.dmpk.2025.101057.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"859_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/acs.chemrestox.9b00186","volume":"33","author":"B Chen","year":"2020","unstructured":"Chen B, Zhang X-D, Wen J, Zhang B, Chen D, Wang S, et al. Effects of 26 recombinant CYP3A4 variants on brexpiprazole metabolism. Chem Res Toxicol. 2020;33(1):172\u201380. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00186.","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"859_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jcph.1946","volume":"62","author":"A Elmokadem","year":"2022","unstructured":"Elmokadem A, Bruno CD, Housand C, Jordie EB, Chow CR, Lesko LJ, et al. Brexpiprazole Pharmacokinetics in CYP2D6 poor metabolizers: using physiologically Based pharmacokinetic modeling to optimize time to effective concentrations. J Sport Hist Clin Pharma. 2022;62(1):66\u201375. https:\/\/doi.org\/10.1002\/jcph.1946.","journal-title":"J Sport Hist Clin Pharma"},{"issue":"2","key":"859_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/cpt.2791","volume":"113","author":"T Frederiksen","year":"2023","unstructured":"Frederiksen T, Areberg J, Raoufinia A, Schmidt E, Stage TB, Br\u00f8sen K. Estimating the in vivo function of CYP2D6 Alleles through Population pharmacokinetic modeling of brexpiprazole. Clin Pharma Ther. 2023;113(2):360\u201369. https:\/\/doi.org\/10.1002\/cpt.2791.","journal-title":"Clin Pharma Ther"},{"issue":"3","key":"859_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s13318-020-00606-8","volume":"45","author":"D Thakkar","year":"2020","unstructured":"Thakkar D, Kate AS. 1-(Benzo[B]thiophen-4-yl)piperazine ring Induced bioactivation of brexpiprazole in liver microsomes: identification and characterization of reactive conjugates using ultra-high-Performance Liquid Chromatography\/Quadrupole time-of-flight Mass spectrometry. Eur J Drug Metab Pharmacokinet. 2020;45(3):393\u2013403. https:\/\/doi.org\/10.1007\/s13318-020-00606-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"859_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"859_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/17425255.2025.2517731","volume":"21","author":"A Basi\u0144ska-Ziobro\u0144","year":"2025","unstructured":"Basi\u0144ska-Ziobro\u0144 A, Danek PJ, Daniel WA. The effect of prolonged treatment with antipsychotic drugs on cytochrome P450 \u2212 drug metabolizing enzymes. Mechanisms of action and significance for pharmacotherapy. Expert Opin Drug Metab Toxicol. 2025;21(8):921\u201337. https:\/\/doi.org\/10.1080\/17425255.2025.2517731.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"859_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/03602532.2018.1554674","volume":"50","author":"A Haduch","year":"2018","unstructured":"Haduch A, Daniel WA. The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders. Drug Metab Rev. 2018;50(4):415\u201329. https:\/\/doi.org\/10.1080\/03602532.2018.1554674.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"859_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1006\/abbi.1999.1351","volume":"369","author":"DJ Waxman","year":"1999","unstructured":"Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Archives Biochem Biophys. 1999;369(1):11\u201323. https:\/\/doi.org\/10.1006\/abbi.1999.1351.","journal-title":"Archives Biochem Biophys"},{"issue":"4","key":"859_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1124\/pr.55.4.2","volume":"55","author":"C Handschin","year":"2003","unstructured":"Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev. 2003;55(4):649\u201373. https:\/\/doi.org\/10.1124\/pr.55.4.2.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"859_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbi.2005.06.003","volume":"155","author":"XC Kretschmer","year":"2005","unstructured":"Kretschmer XC, Baldwin WS. CAR and PXR: xenosensors of endocrine disrupters? Chemico-Biol Interact. 2005;155(3):111\u201328. https:\/\/doi.org\/10.1016\/j.cbi.2005.06.003.","journal-title":"Chemico-Biol Interact"},{"issue":"6","key":"859_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2174\/1389200033489262","volume":"4","author":"H Wang","year":"2003","unstructured":"Wang H, Negishi M. Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. CDM. 2003;4(6):515\u201325. https:\/\/doi.org\/10.2174\/1389200033489262.","journal-title":"CDM"},{"key":"859_CR29","doi-asserted-by":"publisher","unstructured":"Gnerre C, Bl\u00e4ttler S, Kaufmann MR, Looser R, Meyer UA. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics. 2004;14(10):635\u201345. https:\/\/doi.org\/10.1097\/00008571-200410000-00001.","DOI":"10.1097\/00008571-200410000-00001"},{"issue":"8","key":"859_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1194\/jlr.M400453-JLR200","volume":"46","author":"C Gnerre","year":"2005","unstructured":"Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, Looser R, et al. LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver. J Lipid Res. 2005;46(8):1633\u201342. https:\/\/doi.org\/10.1194\/jlr.M400453-JLR200.","journal-title":"J Lipid Res"},{"issue":"2","key":"859_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.abb.2004.08.030","volume":"433","author":"C Handschin","year":"2005","unstructured":"Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Archives Biochem Biophys. 2005;433(2):387\u201396. https:\/\/doi.org\/10.1016\/j.abb.2004.08.030.","journal-title":"Archives Biochem Biophys"},{"issue":"2","key":"859_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/138920011795016890","volume":"12","author":"M Hafner","year":"2011","unstructured":"Hafner M, Rezen T, Rozman D. Regulation of hepatic cytochromes p450 by lipids and cholesterol. CDM. 2011;12(2):173\u201385. https:\/\/doi.org\/10.2174\/138920011795016890.","journal-title":"CDM"},{"key":"859_CR33","doi-asserted-by":"publisher","unstructured":"Ju\u0159ica J, Dovrt\u011blov\u00e1 G, Noskov\u00e1 K, Zendulka O. Bile acids, nuclear receptors and cytochrome P450. Physiol Res. 2016;65:S427\u201340. https:\/\/doi.org\/10.33549\/physiolres.933512.","DOI":"10.33549\/physiolres.933512"},{"issue":"7","key":"859_CR34","doi-asserted-by":"publisher","first-page":"166133","DOI":"10.1016\/j.bbadis.2021.166133","volume":"1867","author":"K Panzitt","year":"2021","unstructured":"Panzitt K, Wagner M. FXR in liver physiology: multiple faces to regulate liver metabolism. Biochim Et Biophys Acta (BBA) - Mol Basis Disease. 2021;1867(7):166133. https:\/\/doi.org\/10.1016\/j.bbadis.2021.166133.","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"key":"859_CR35","first-page":"9","volume":"2","author":"J Chen","year":"2014","unstructured":"Chen J, Zhao K-N, Chen C. The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Ann. Transl. Med. 2014;2:9.","journal-title":"Ann. Transl. Med"},{"key":"859_CR36","doi-asserted-by":"publisher","first-page":"111471","DOI":"10.1016\/j.cbi.2025.111471","volume":"412","author":"C Chen","year":"2025","unstructured":"Chen C, Lin P, Wu Z, Lin Y, Huang M, He L, et al. Farnesoid X receptor regulates CYP1A1 and CYP1B1 and estradiol metabolism in mouse and human cell lines. Chemico-Biol Interact. 2025;412:111471. https:\/\/doi.org\/10.1016\/j.cbi.2025.111471.","journal-title":"Chemico-Biol Interact"},{"issue":"12","key":"859_CR37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","volume":"17","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry. 2012;17(12):1206\u201327. https:\/\/doi.org\/10.1038\/mp.2012.47.","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"859_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","volume":"19","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry. 2018;19(3):162\u201374. https:\/\/doi.org\/10.1080\/15622975.2018.1439595.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"859_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jcph.979","volume":"58","author":"J Ishigooka","year":"2018","unstructured":"Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and Safety of brexpiprazole following Multiple-dose administration to Japanese patients with schizophrenia. J Sport Hist Clin Pharma. 2018;58(1):74\u201380. https:\/\/doi.org\/10.1002\/jcph.979.","journal-title":"J Sport Hist Clin Pharma"},{"issue":"7","key":"859_CR40","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/ph14070629","volume":"14","author":"PJ Danek","year":"2021","unstructured":"Danek PJ, Bromek E, Daniel WA. The influence of long-term treatment with asenapine on liver cytochrome P450 expression and activity in the rat. The Involvement of different mechanisms. Pharmaceuticals (Basel). 2021;14(7):629. https:\/\/doi.org\/10.3390\/ph14070629.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"859_CR41","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.3390\/ijms22168447","volume":"22","author":"PJ Danek","year":"2021","unstructured":"Danek PJ, Kuban W, Daniel WA. The effect of chronic iloperidone treatment on cytochrome P450 expression and activity in the rat liver: involvement of neuroendocrine mechanisms. IJMS. 2021;22(16):8447. https:\/\/doi.org\/10.3390\/ijms22168447.","journal-title":"IJMS"},{"issue":"23","key":"859_CR42","doi-asserted-by":"publisher","first-page":"16796","DOI":"10.3390\/ijms242316796","volume":"24","author":"PJ Danek","year":"2023","unstructured":"Danek PJ, Daniel WA. The novel atypical antipsychotic lurasidone affects cytochrome P450 expression in the liver and peripheral blood lymphocytes. IJMS. 2023;24(23):16796. https:\/\/doi.org\/10.3390\/ijms242316796.","journal-title":"IJMS"},{"issue":"4","key":"859_CR43","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s43440-024-00608-2","volume":"76","author":"PJ Danek","year":"2024","unstructured":"Danek PJ, Daniel WA. The effect of new atypical antipsychotic drugs on the expression of transcription factors regulating cytochrome P450 enzymes in rat liver. Pharmacol Rep. 2024;76(4):895\u2013901. https:\/\/doi.org\/10.1007\/s43440-024-00608-2.","journal-title":"Pharmacol Rep"},{"key":"859_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.plipres.2017.06.001","volume":"67","author":"DW Nebert","year":"2017","unstructured":"Nebert DW. Aryl hydrocarbon receptor (AHR): \u201cpioneer member\u201d of the basic-helix\/loop\/helix per-arnt-sim (bHLH\/PAS) family of \u201csensors\u201d of foreign and endogenous signals. Prog Lipid Res. 2017;67:38\u201357. https:\/\/doi.org\/10.1016\/j.plipres.2017.06.001.","journal-title":"Prog Lipid Res"},{"issue":"6","key":"859_CR45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875\u201394. https:\/\/doi.org\/10.1517\/17425255.2.6.875.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"859_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.apsb.2019.11.016","volume":"10","author":"J Lu","year":"2020","unstructured":"Lu J, Shang X, Zhong W, Xu Y, Shi R, Wang X. New insights of CYP1A in endogenous metabolism: a focus on single nucleotide polymorphisms and diseases. Acta Pharmaceutica Sin. B. 2020;10(1):91\u2013104. https:\/\/doi.org\/10.1016\/j.apsb.2019.11.016.","journal-title":"Acta Pharmaceutica Sin. B"},{"issue":"3","key":"859_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.taap.2003.11.029","volume":"199","author":"T Su","year":"2004","unstructured":"Su T. Regulation of the cytochrome P450 2A genes. Toxicol Appl Pharm. 2004;199(3):285\u201394. https:\/\/doi.org\/10.1016\/j.taap.2003.11.029.","journal-title":"Toxicol Appl Pharm"},{"issue":"1","key":"859_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105349","volume":"48","author":"J-M Pascussi","year":"2008","unstructured":"Pascussi J-M, Gerbal-Chaloin S, Duret C, Daujat-Chavanieu M, Vilarem M-J, Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol. 2008;48(1):1\u201332. https:\/\/doi.org\/10.1146\/annurev.pharmtox.47.120505.105349.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"13","key":"859_CR49","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","volume":"62","author":"AH Tolson","year":"2010","unstructured":"Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62(13):1238\u201349. https:\/\/doi.org\/10.1016\/j.addr.2010.08.006.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"859_CR50","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bbagrm.2016.02.013","volume":"1859","author":"SC Chai","year":"2016","unstructured":"Chai SC, Cherian MT, Wang Y-M, Chen T. Small-molecule modulators of PXR and CAR. Biochim Et Biophys Acta (BBA) - Gene Regul Mechanisms. 2016;1859(9):1141\u201354. https:\/\/doi.org\/10.1016\/j.bbagrm.2016.02.013.","journal-title":"Biochim Et Biophys Acta (BBA) - Gene Regul Mechanisms"},{"key":"859_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neuroscience.2018.03.009","volume":"379","author":"F Zhang","year":"2018","unstructured":"Zhang F, Li J, Na S, Wu J, Yang Z, Xie X, et al. The Involvement of PPARs in the selective regulation of brain CYP2D by growth hormone. Neuroscience. 2018;379:115\u201325. https:\/\/doi.org\/10.1016\/j.neuroscience.2018.03.009.","journal-title":"Neuroscience"},{"issue":"1\u20132","key":"859_CR52","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11010-005-9038-x","volume":"284","author":"O Ito","year":"2006","unstructured":"Ito O, Nakamura Y, Tan L, Ishizuka T, Sasaki Y, Minami N, et al. Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol Cell Biochem. 2006;284(1\u20132):141\u201348. https:\/\/doi.org\/10.1007\/s11010-005-9038-x.","journal-title":"Mol Cell Biochem"},{"key":"859_CR53","doi-asserted-by":"publisher","unstructured":"Paul PR, Mishra MK, Bora S, Kukal S, Singh A, Kukreti S, et al. The impact of P-Glycoprotein on CNS drug efflux and variability in response. J Biochem Mol Tox. 2025;39(3):e70190. https:\/\/doi.org\/10.1002\/jbt.70190.","DOI":"10.1002\/jbt.70190"},{"issue":"23","key":"859_CR54","doi-asserted-by":"publisher","first-page":"14667","DOI":"10.3390\/ijms232314667","volume":"23","author":"AB Chai","year":"2022","unstructured":"Chai AB, Callaghan R, Gelissen IC. Regulation of P-Glycoprotein in the brain. Int J Mol Sci. 2022;23(23):14667. https:\/\/doi.org\/10.3390\/ijms232314667.","journal-title":"IJMS"},{"issue":"6","key":"859_CR55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1517\/17425250902973703","volume":"5","author":"J W\u00f3jcikowski","year":"2009","unstructured":"W\u00f3jcikowski J, Daniel WA. The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. Expert Opin Drug Metab Toxicol. 2009;5(6):631\u201345. https:\/\/doi.org\/10.1517\/17425250902973703.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"859_CR56","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.bcp.2013.07.017","volume":"86","author":"A Sadakierska-Chudy","year":"2013","unstructured":"Sadakierska-Chudy A, Haduch A, Rysz M, Go\u0142embiowska K, Daniel WA. The role of brain noradrenergic system in the regulation of liver cytochrome P450 expression. Biochemical Pharmacol. 2013;86(6):800\u201307. https:\/\/doi.org\/10.1016\/j.bcp.2013.07.017.","journal-title":"Biochemical Pharmacol"},{"key":"859_CR57","doi-asserted-by":"publisher","first-page":"115006","DOI":"10.1016\/j.bcp.2022.115006","volume":"199","author":"WA Daniel","year":"2022","unstructured":"Daniel WA, Bromek E, Danek PJ, Haduch A. The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug-drug interactions. Biochemical Pharmacol. 2022;199:115006. https:\/\/doi.org\/10.1016\/j.bcp.2022.115006.","journal-title":"Biochemical Pharmacol"},{"issue":"4","key":"859_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/17425255.2021.1872543","volume":"17","author":"E Bromek","year":"2021","unstructured":"Bromek E, Daniel WA. The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models. Expert Opin Drug Metab Toxicol. 2021;17(4):413\u201324. https:\/\/doi.org\/10.1080\/17425255.2021.1872543.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"859_CR59","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1210\/me.2006-0007","volume":"20","author":"DJ Waxman","year":"2006","unstructured":"Waxman DJ, O\u2019Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20(11):2613\u201329. https:\/\/doi.org\/10.1210\/me.2006-0007.","journal-title":"Mol Endocrinol"},{"issue":"4","key":"859_CR60","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/03602530903112284","volume":"41","author":"K Monostory","year":"2009","unstructured":"Monostory K, Pascussi J-M, K\u00f3bori L, Dvorak Z. Hormonal regulation of CYP1A expression. Drug Metab Rev. 2009;41(4):547\u201372. https:\/\/doi.org\/10.1080\/03602530903112284.","journal-title":"Drug Metab Rev"},{"issue":"2","key":"859_CR61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/138920011795016854","volume":"12","author":"K Monostory","year":"2011","unstructured":"Monostory K, Dvorak Z. Steroid regulation of drug-metabolizing cytochromes P450. CDM. 2011;12(2):154\u201372. https:\/\/doi.org\/10.2174\/138920011795016854.","journal-title":"CDM"},{"issue":"1","key":"859_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1006\/abbi.2000.1704","volume":"376","author":"TA Kocarek","year":"2000","unstructured":"Kocarek TA, Zangar RC, Novak RF. Post-transcriptional regulation of rat CYP2E1 expression: role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Archives Biochem Biophys. 2000;376(1):180\u201390. https:\/\/doi.org\/10.1006\/abbi.2000.1704.","journal-title":"Archives Biochem Biophys"},{"key":"859_CR63","doi-asserted-by":"publisher","unstructured":"Liu Y, Xu Q, Liu Y, Cao S, Luo J, Zheng Z, et al. Hepatocyte-targeted Lipid nanoparticle delivery of HERC2 plasmid controls drug-Induced hepatotoxicity by limiting \u03b2-catenin-regulated CYP2E1 expression. Adv Sci. 2024;11(46):e2401633. https:\/\/doi.org\/10.1002\/advs.202401633.","DOI":"10.1002\/advs.202401633"},{"issue":"2","key":"859_CR64","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/03602532.2019.1632889","volume":"51","author":"J Chen","year":"2019","unstructured":"Chen J, Jiang S, Wang J, Renukuntla J, Sirimulla S, Chen J. A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism. Drug Metab Rev. 2019;51(2):178\u201395. https:\/\/doi.org\/10.1080\/03602532.2019.1632889.","journal-title":"Drug Metab Rev"},{"key":"859_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2023.08.028","volume":"261","author":"G Cereda","year":"2023","unstructured":"Cereda G, Lazzaretti M, Colli C, Fontana E, Enrico P, Pigoni A, et al. Pharmacokinetic drug-drug interaction between clozapine and brexpiprazole: a case series. Schizophr Res. 2023;261:15\u201317. https:\/\/doi.org\/10.1016\/j.schres.2023.08.028.","journal-title":"Schizophr Res"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00859-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:52:16Z","timestamp":1781682736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00859-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00859-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}